BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35641658)

  • 21. The histopathology of BRAF-V600E-mutated lung adenocarcinoma.
    Yousem SA; Nikiforova M; Nikiforov Y
    Am J Surg Pathol; 2008 Sep; 32(9):1317-21. PubMed ID: 18636014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological and molecular characterization of resected lung adenocarcinoma: Correlations with histopathological grading systems in Chinese patients.
    Xia W; Zhang S; Ye Y; Xiao H; Zhang Y; Ning G; Zhang Y; Wang W; Fei GH
    Pathol Res Pract; 2024 Jul; 259():155359. PubMed ID: 38810376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated whole-exome and bulk transcriptome sequencing delineates the dynamic evolution from preneoplasia to invasive lung adenocarcinoma featured with ground-glass nodules.
    Zhou D; Li YQ; Liu QX; Deng XF; Chen L; Li MY; Zhang J; Lu X; Zheng H; Dai JG
    Cancer Med; 2024 Jun; 13(11):e7383. PubMed ID: 38864483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of intratumoral heterogeneity of oncogenic driver mutations in surgically-resected lung adenocarcinoma: implications of percutaneous biopsy-based molecular assay for target-directed therapy.
    Kim HK; Lee HY; Choi YL; Choi SJ; Choi H; Lee J; Han J; Ahn MJ; Lee KS; Kim J
    Anticancer Res; 2014 Feb; 34(2):707-14. PubMed ID: 24511003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncogenic mutations within the β3-αC loop of EGFR/ERBB2/BRAF/MAP2K1 predict response to therapies.
    Zhang B; Chen Y; Dai P; Yu H; Ma J; Chen C; Zhang Y; Guan Y; Chen R; Liu T; Wang J; Yang L; Yi X; Xia X; Ma H
    Mol Genet Genomic Med; 2020 Oct; 8(10):e1395. PubMed ID: 32757330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine.
    Wright GM; Do H; Weiss J; Alam NZ; Rathi V; Walkiewicz M; John T; Russell PA; Dobrovic A
    Oncotarget; 2014 Apr; 5(8):2107-15. PubMed ID: 24742923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
    Arcila ME; Nafa K; Chaft JE; Rekhtman N; Lau C; Reva BA; Zakowski MF; Kris MG; Ladanyi M
    Mol Cancer Ther; 2013 Feb; 12(2):220-9. PubMed ID: 23371856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation.
    Ding X; Zhang Z; Jiang T; Li X; Zhao C; Su B; Zhou C
    Cancer Med; 2017 Mar; 6(3):555-562. PubMed ID: 28135039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
    Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
    PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
    Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
    Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
    Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
    Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
    Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.
    Singh V; Guleria P; Malik PS; Mohan A; Thulkar S; Pandey RM; Luthra K; Arava S; Ray R; Jain D
    Curr Probl Cancer; 2019 Oct; 43(5):391-401. PubMed ID: 30591192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
    Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
    J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.
    Wu C; Zhao C; Yang Y; He Y; Hou L; Li X; Gao G; Shi J; Ren S; Chu H; Zhou C; Zhang J; Schmid-Bindert G
    J Thorac Oncol; 2015 May; 10(5):778-783. PubMed ID: 25629635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic predictors of MEK dependence in non-small cell lung cancer.
    Pratilas CA; Hanrahan AJ; Halilovic E; Persaud Y; Soh J; Chitale D; Shigematsu H; Yamamoto H; Sawai A; Janakiraman M; Taylor BS; Pao W; Toyooka S; Ladanyi M; Gazdar A; Rosen N; Solit DB
    Cancer Res; 2008 Nov; 68(22):9375-83. PubMed ID: 19010912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic Alterations in Preinvasive Lung Synchronous Lesions.
    Ahn S; Lim J; Park SY; Kim H; Kwon HJ; Han YB; Lee CT; Cho S; Chung JH
    Cancer Res Treat; 2020 Oct; 52(4):1120-1134. PubMed ID: 32599981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
    Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
    BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.
    Trejo CL; Green S; Marsh V; Collisson EA; Iezza G; Phillips WA; McMahon M
    Cancer Res; 2013 Nov; 73(21):6448-61. PubMed ID: 24019382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Braf kinase-inactive mutant induces lung adenocarcinoma.
    Nieto P; Ambrogio C; Esteban-Burgos L; Gómez-López G; Blasco MT; Yao Z; Marais R; Rosen N; Chiarle R; Pisano DG; Barbacid M; Santamaría D
    Nature; 2017 Aug; 548(7666):239-243. PubMed ID: 28783725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.